Tyme Technologies, Inc., a biotechnology company developing cancer metabolism-based therapies, completed its acquisition by merger with Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes. A cross-office, cross-practice team of Faegre Drinker attorneys supported Tyme in the transaction, which closed on September 16, 2022.
Read the full press release for more information on the deal.
Results may vary depending on your particular facts and legal circumstances.
